Lucentis Sales Data
| Rank 26 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Lucentis U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 26 | $460,621 | -0.84% | 275 | 0.36% |
| Q3 2013 | 26 ( 1) |
$464,500 | 2.52% | 274 | 2.62% |
| Q2 2013 | 27 (2) |
$453,064 | 9.07% | 267 | 10.33% |
| Q1 2013 | 29 (1) |
$415,406 | 4.92% | 242 | 6.14% |
| Q4 2012 | 30 (1) |
$395,931 | 3.63% | 228 | 7.04% |
| Q3 2012 | 31 (6) |
$382,048 | -1.88% | 213 | n/a |
| Q2 2012 | 37 ( 2) |
$389,387 | -4.92% | 213 | -4.91% |
| Q1 2012 | 35 (5) |
$409,547 | -6.89% | 224 | -5.88% |
| Q4 2011 | 30 (2) |
$439,867 | 2.44% | 238 | 2.59% |
| Q3 2011 | 28 (2) |
$429,393 | 1.13% | 232 | 0.87% |
| Q2 2011 | 30 (3) |
$424,611 | 0.95% | 230 | 1.32% |
| Q1 2011 | 33 | $420,635 | n/a | 227 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
